Edwards Lifesciences EW Payments to Acquire Held-to-Maturity Securities
Payments to Acquire Held-to-Maturity Securities at other companies
Other financials
Where this comes from
Reported directly by Edwards Lifesciences in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireHeldToMaturitySecurities.
The official record: Edwards Lifesciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edwards Lifesciences's payments to acquire held-to-maturity securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edwards Lifesciences's payments to acquire held-to-maturity securities?
- Edwards Lifesciences (EW) reported payments to acquire held-to-maturity securities of $12.5M in Q1 2026.
- How has Edwards Lifesciences's payments to acquire held-to-maturity securities changed year-over-year?
- Edwards Lifesciences's payments to acquire held-to-maturity securities decreased by 2.3% year-over-year, from $12.8M to $12.5M.
- What is the long-term trend for Edwards Lifesciences's payments to acquire held-to-maturity securities?
- Over 4 years (2021 to 2025), Edwards Lifesciences's payments to acquire held-to-maturity securities has grown at a -35.5% compound annual growth rate (CAGR), from $250M to $43.3M.
- What does payments to acquire held-to-maturity securities mean?
- Cash outflows dedicated to purchasing debt securities that the company has the positive intent and ability to hold until maturity. This reflects the management of excess cash reserves in low-risk, fixed-income instruments.